These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22765900)

  • 1. Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors.
    Liu KK; Bailey S; Dinh DM; Lam H; Li C; Wells PA; Yin MJ; Zou A
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5114-7. PubMed ID: 22765900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR.
    Le PT; Cheng H; Ninkovic S; Plewe M; Huang X; Wang H; Bagrodia S; Sun S; Knighton DR; LaFleur Rogers CM; Pannifer A; Greasley S; Dalvie D; Zhang E
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5098-103. PubMed ID: 22749419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.
    Peterson EA; Boezio AA; Andrews PS; Boezio CM; Bush TL; Cheng AC; Choquette D; Coats JR; Colletti AE; Copeland KW; DuPont M; Graceffa R; Grubinska B; Kim JL; Lewis RT; Liu J; Mullady EL; Potashman MH; Romero K; Shaffer PL; Stanton MK; Stellwagen JC; Teffera Y; Yi S; Cai T; La DS
    Bioorg Med Chem Lett; 2012 Aug; 22(15):4967-74. PubMed ID: 22765895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor.
    Finlay MR; Buttar D; Critchlow SE; Dishington AP; Fillery SM; Fisher E; Glossop SC; Graham MA; Johnson T; Lamont GM; Mutton S; Perkins P; Pike KG; Slater AM
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4163-8. PubMed ID: 22607682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors.
    Poulsen A; Williams M; Nagaraj HM; William AD; Wang H; Soh CK; Xiong ZC; Dymock B
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1009-13. PubMed ID: 22197143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
    Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
    Liu KK; Bagrodia S; Bailey S; Cheng H; Chen H; Gao L; Greasley S; Hoffman JE; Hu Q; Johnson TO; Knighton D; Liu Z; Marx MA; Nambu MD; Ninkovic S; Pascual B; Rafidi K; Rodgers CM; Smith GL; Sun S; Wang H; Yang A; Yuan J; Zou A
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6096-9. PubMed ID: 20817449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.
    Liu KK; Huang X; Bagrodia S; Chen JH; Greasley S; Cheng H; Sun S; Knighton D; Rodgers C; Rafidi K; Zou A; Xiao J; Yan S
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1270-4. PubMed ID: 21269826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
    Cheng H; Hoffman JE; Le PT; Pairish M; Kania R; Farrell W; Bagrodia S; Yuan J; Sun S; Zhang E; Xiang C; Dalvie D; Rahavendran SV
    Bioorg Med Chem Lett; 2013 May; 23(9):2787-92. PubMed ID: 23506825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors.
    Stec MM; Andrews KL; Bo Y; Caenepeel S; Liao H; McCarter J; Mullady EL; San Miguel T; Subramanian R; Tamayo N; Whittington DA; Wang L; Wu T; Zalameda LP; Zhang N; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4136-42. PubMed ID: 26298499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.
    Mortensen DS; Sapienza J; Lee BG; Perrin-Ninkovic SM; Harris R; Shevlin G; Parnes JS; Whitefield B; Hickman M; Khambatta G; Bisonette RR; Peng S; Gamez JC; Leisten J; Narla RK; Fultz KE; Sankar S
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1588-91. PubMed ID: 23414803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.
    Sutherlin DP; Baker S; Bisconte A; Blaney PM; Brown A; Chan BK; Chantry D; Castanedo G; DePledge P; Goldsmith P; Goldstein DM; Hancox T; Kaur J; Knowles D; Kondru R; Lesnick J; Lucas MC; Lewis C; Murray J; Nadin AJ; Nonomiya J; Pang J; Pegg N; Price S; Reif K; Safina BS; Salphati L; Staben S; Seward EM; Shuttleworth S; Sohal S; Sweeney ZK; Ultsch M; Waszkowycz B; Wei B
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4296-302. PubMed ID: 22672799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.
    Martínez González S; Hernández AI; Varela C; Lorenzo M; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán MI; Alfonso P; García-Serelde B; Mateos G; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Blanco-Aparicio C; Pastor J
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5208-14. PubMed ID: 22819764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
    Lee W; Ortwine DF; Bergeron P; Lau K; Lin L; Malek S; Nonomiya J; Pei Z; Robarge KD; Schmidt S; Sideris S; Lyssikatos JP
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5097-104. PubMed ID: 23932790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.
    Malagu K; Duggan H; Menear K; Hummersone M; Gomez S; Bailey C; Edwards P; Drzewiecki J; Leroux F; Quesada MJ; Hermann G; Maine S; Molyneaux CA; Le Gall A; Pullen J; Hickson I; Smith L; Maguire S; Martin N; Smith G; Pass M
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5950-3. PubMed ID: 19762236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.
    Smith AL; D'Angelo ND; Bo YY; Booker SK; Cee VJ; Herberich B; Hong FT; Jackson CL; Lanman BA; Liu L; Nishimura N; Pettus LH; Reed AB; Tadesse S; Tamayo NA; Wurz RP; Yang K; Andrews KL; Whittington DA; McCarter JD; Miguel TS; Zalameda L; Jiang J; Subramanian R; Mullady EL; Caenepeel S; Freeman DJ; Wang L; Zhang N; Wu T; Hughes PE; Norman MH
    J Med Chem; 2012 Jun; 55(11):5188-219. PubMed ID: 22548365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
    Dehnhardt CM; Venkatesan AM; Chen Z; Delos-Santos E; Ayral-Kaloustian S; Brooijmans N; Yu K; Hollander I; Feldberg L; Lucas J; Mallon R
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4773-8. PubMed ID: 21763134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.
    Menear KA; Gomez S; Malagu K; Bailey C; Blackburn K; Cockcroft XL; Ewen S; Fundo A; Le Gall A; Hermann G; Sebastian L; Sunose M; Presnot T; Torode E; Hickson I; Martin NM; Smith GC; Pike KG
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5898-901. PubMed ID: 19733066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
    Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.
    Venkatesan AM; Chen Z; dos Santos O; Dehnhardt C; Santos ED; Ayral-Kaloustian S; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Chaudhary I; Mansour TS
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5869-73. PubMed ID: 20797855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.